Umbrella Trial

An umbrella trial is a clinical trial design that evaluates multiple investigational therapies within a single disease population under one overarching master protocol, with each treatment arm matched to a different biomarker or molecular subtype found within that disease. Where a conventional single-arm or two-arm trial tests one intervention against one population, an umbrella trial keeps the disease constant and stratifies patients into several concurrently open, biomarker-defined sub-studies — each typically evaluating a different targeted therapy suited to that specific molecular alteration.

The U.S. Food and Drug Administration formally recognizes the umbrella trial as one of three related master protocol designs — alongside the basket trial and the platform trial — in its guidance Master Protocols: Efficient Clinical Trial Design Strategies To Expedite Development of Oncology Drugs and Biologics; Guidance for Industry, finalized and announced in the Federal Register on March 2, 2022. FDA defines a master protocol generally as a single protocol designed with multiple substudies, which may have different objectives, evaluating one or more investigational drugs across one or more diseases within a single overall study structure.

What makes a trial an umbrella trial

Three features distinguish the design in practice:

• One disease, many drugs. Every arm enrolls patients from the same disease population; what varies is the investigational therapy each arm tests.
• Biomarker-matched arms. Patients are screened, typically through a companion master screening protocol, and assigned to the sub-study arm whose targeted therapy matches the specific mutation or biomarker their disease carries.
• A fixed, pre-specified arm roster. Unlike a platform trial, the set of arms in an umbrella trial is generally defined before the trial opens rather than added or dropped on an open-ended, ongoing basis — though a closed arm can be replaced with a new one as a protocol amendment if the biomarker landscape or drug-development pipeline changes.

Umbrella trial vs. basket trial vs. platform trial

All three are master-protocol designs built around one overarching protocol governing multiple sub-studies, but the organizing logic differs:

• Umbrella trial: one disease, multiple drugs, each matched to a different biomarker.
• Basket trial: one drug (or fixed combination), evaluated across multiple diseases that share a biomarker.
• Platform trial: an ongoing, perpetual infrastructure in which arms are added or dropped over time against a shared, persistent control, rather than a fixed roster set at the outset.

See Basket Trial: basket trial vs. umbrella trial for the reversed comparison, and Platform Trial for how the perpetual, arm-churning design differs operationally from both fixed-roster designs.

Regulatory and administrative implications

Because an umbrella trial’s arm roster is generally fixed at the outset, the sponsor typically works out the full menu of biomarker-matched sub-studies, the master screening protocol that routes patients to them, and the shared infrastructure (data management, safety monitoring, statistical analysis plan) before the trial opens — in contrast to a platform trial’s rolling, open-ended arm additions. FDA generally recommends a master protocol be submitted as a single Investigational New Drug (IND) application, with a pre-IND meeting to align on the sub-study design, the screening and matching algorithm, and each arm’s statistical analysis before enrollment begins. If a sub-study closes early (for futility, safety, or because the sponsoring company withdraws the drug) and is replaced with a new biomarker-matched arm, that change is typically handled as a substantial protocol amendment to the existing master protocol and IND rather than as a new trial. FDA’s guidance also recommends centralized, single-IRB review across all sites and sub-studies — see Independent Ethics Committee (IEC) — and centralized documentation of the master protocol, the screening protocol, and each sub-study appendix in the trial’s Trial Master File (TMF).

Real example: Lung-MAP

The Lung-MAP trial (SWOG S1400), formally titled the Lung Master Protocol, is a widely documented umbrella trial in previously treated advanced non-small cell lung cancer. Launched in 2014 and sponsored by SWOG, a National Cancer Institute-funded cooperative research group, Lung-MAP uses a master genomic screening protocol to test each enrolled patient’s tumor for a defined panel of actionable mutations, then assigns the patient to whichever biomarker-matched investigational drug sub-study fits their result, with a non-match sub-study (commonly evaluating immunotherapy) available for patients whose tumors carry none of the targeted alterations. The disease population stays fixed throughout; only the arm assignment varies, by biomarker — the defining structure of an umbrella trial.

Why the distinction matters for research administration

Correctly identifying a protocol as an umbrella, basket, or platform trial (or a hybrid) affects how research administrators, IRB staff, and regulatory-affairs teams should expect the trial to be governed: an umbrella trial typically means one master protocol plus a companion screening protocol plus per-arm substudy appendices, substudy-level amendments when an arm is replaced rather than whole-new-protocol submissions, and shared infrastructure (screening, safety monitoring, data management) across the biomarker-matched arms. For the broader design taxonomy this fits within, see Clinical Study Design: The Major Types and How They Relate. For the practical mechanics of building out a trial’s endpoints, sample size, randomization, and statistical analysis plan, see Designing a Clinical Trial: Endpoints, Sample Size, Randomization, SAP, and for how adaptive statistical elements often pair with master-protocol designs, see Adaptive Design in Clinical Trials.